Prospective Validation of the Eleveld Model of Propofol for Procedural Sedation in Adults.
Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Mar 14, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called the "Eleveld Model of Propofol for Procedural Sedation in Adults," is studying how to better use a medication called propofol to safely sedate adults during certain procedures. The researchers want to find the right amount of propofol that works best for different levels of sedation, which is the state of being calm and relaxed while still being monitored. They will use special tools to measure how alert or sedated participants are during the process, and they will closely observe their vital signs to ensure safety.
To be eligible for this study, participants need to be adults between 18 and 80 years old who are scheduled for sedation at the UMCG hospital between January 1, 2024, and January 1, 2025. Those with certain conditions or who are using specific medications may not qualify. If you join the trial, you can expect to receive propofol in a controlled way, and your level of sedation will be checked regularly. This study aims to improve sedation practices, making procedures safer and more comfortable for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients for procedural sedation in the UMCG between 01-01-2024 and 01-01-2025.
- Exclusion Criteria:
- • Age \<18 years; use of esketamine during the procedure, use of benzodiazepines prior or during the procedure, hearing disability, BIS quality index \< 50
About University Medical Center Groningen
University Medical Center Groningen (UMCG) is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and extensive education in the medical field. As a prominent sponsor of clinical trials, UMCG leverages its multidisciplinary expertise and state-of-the-art facilities to advance medical knowledge and improve therapeutic outcomes. The center fosters collaboration among researchers, healthcare professionals, and industry partners, aiming to translate scientific discoveries into effective treatments that enhance patient health and well-being. With a focus on ethical standards and regulatory compliance, UMCG is dedicated to conducting clinical trials that contribute to the advancement of medicine and the betterment of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Mendy Driesens, MSc
Principal Investigator
University Medical Center Groningen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported